CN code 3002 14 00 Immunological products, mixed, not put up in measured doses or in forms or…

TARIC codes (10 digits): 1

Origin, preferential duty and next steps ›

Examples from the EU database of Binding Tariff Information (BTI). A ruling binds only its holder and many have expired — read them as guidance, not as a decision for your product.

• PEMBROLIZUMAB DRUG SUBSTANCE (FINAL FORMULATED BULK - FFB) THE PRODUCT IS USED FOR PHARMACEUTICAL (BIOLOGIC IMMUNOLOGICAL). THE PRODUCT IS PRODUCED IN BULK AS A FROZEN LIQUID AND HAS A COLOURLESS TO PALE YELLOW APPEARANCE.

  3002 14 00 · IE 2022 · IEBTIIENEN004-2022-BTI268

• MK-6072 (BEZLOTOXUMAB) FFB. (FINAL FORMULATED BULK). FOR PHARMACEUTICAL (BIOLOGIC/IMMUNOLOGICAL DRUG SUBSTANCE)USE. IT IS BEING IMPORTED IN BULK AS A FROZEN LIQUID. IT IS COLOURLESS TO PALE YELLOW IN APPEARANCE.

  3002 14 00 · IE 2018 · IEBTI17NT-14-5932-03

• PEMBROLIZUMAB FFB (FINAL FORMULATED BULK) FOR PHARMACEUTICAL (BIOLOGIC IMMUNOLOGICAL DRUG SUBSTANCE) USE. IMPORTED IN BULK AS A FROZEN LIQUID. IT IS COLOURLESS TO PALE YELLOW IN APPEARANCE.

  3002 14 00 · IE 2018 · IEBTI17NT-14-5932-01

• MK-1308 FFB (FINAL FORMULATED BULK) FOR PHARMACEUTICAL (BIOLOGIC/IMMUNOLOGICAL DRUG SUBSTANCE)USE. THE PRODUCT IS BEING IMPORTED IN BULK AS A FROZEN LIQUID. THE PRODUCT IS COLOURLESS TO PALE YELLOW IN APPEARANCE.

  3002 14 00 · IE 2018 · IEBTI17NT-14-5932-02

• MEDICAMENT WHICH IS PUT TO TREAT RHEUMATOID ARTHRITIS : ITS ACTIVE SUBSTANCE HAS IMMUNOLOGICAL PROPERTIES. PRODUCT IS MIXED AND NOT PUT UP IN MEASURED DOSES OR IN FORMS OR PACKINGS FOR RETAIL SALE

  3002 14 00 · IE 2017 · IE15NT-14-5117-04A

• THE IMMUNOASSAY DIAGNOSTICS REAGENTS AT BECKMAN COULTER IN A CHEMICAL REACTION TO DETECT ANALYSE OR PRODUCE ANOTHER SUBSTANCE WHICH INDICATES THE PRESENT OF A SPECIAL CONDITION. BECKMAN PRODUCE A WIDE RANGE OF REAGENTS. THESE ARE ALL USED 'IN VITRO' WHICH MEANS A REAGENT IS USED FOR THE EXAMINATION OF BLOOD AND TISSUE EXTRACTED FROM THE HUMAN BODY, SOLELY OR PRINCIPALLY FOR THE PURPOSE OF…

  3002 14 00 · IE 2017 · IE17NT-14-4907

• (ENB-0040), ALSO KNOWN AS STRENSIQ, IS A TARGETED ENZYME REPLACEMENT THERAPY DESIGNED TO ADDRESS THE UNDERLYING CAUSE OF HYPOPHOSPHATASIA (HPP) BY NORMALIZING THE GENETICALLY DEFECTIVE METABOLIC PROCESS, AND PREVENTING OR REVERSING THE SEVERE AND LIFE-THREATENING COMPLICATIONS OF LIFE-LONG DYSREGULATED MINERAL METABOLISM. ITS MAIN COMPONENT ASFOTASE ALFA IS A RECOMBINANT FUSION PROTEIN COMPRISED…

  3002 14 00 · GB 2017 · GB503413887

• SOLIRIS IS A THERAPY SPECIFICALLY TESTED AND APPROVED FOR THE TREATMENT OF PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH), AN ULTRA-RARE, LIFE-THREATENING BLOOD DISORDER. SOLIRIS HAS BEEN APPROVED FOR THE TREATMENT OF PATIENTS WITH PNH IN NEARLY 50 COUNTRIES WORLDWIDE. SOLIRIS 300 MG/30ML IS A FORMULATION OF ECULIZUMAB WHICH IS A RECOMBINANT HUMANIZED MONOCLONAL IGG2/4;κ ANTIBODY…

  3002 14 00 · GB 2017 · GB503413593